Clinical Trial

Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity

Name: Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity — clinical trial record (NCT07572175)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SPARTACUS

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.

Trial Details

NCT Number	NCT07572175
Lead Sponsor	Icahn School of Medicine at Mount Sinai Collaborators: American Heart Association
Conditions	Anthracycline-induced Cardiotoxicity, Lymphoma, Chemotherapy, Cardiotoxicity
Enrollment	60 participants
Start Date	2026-07
Primary Completion	2029-06 (estimated)
Study Completion	2029-10 (estimated)
Updated on ClinicalTrials.gov	2026-05-07